Summary
Psychopharmacological treatments in psychiatry are often surprises. Original targets frequently fail, and when successful, may only be the opening volley in a series of ever more important therapeutic applications. Drug development may begin by hypothesis-driven targeting of therapeutic indications with an agent of known and novel mechanism of action. Although this may generate a highly feasible therapeutic indication and can proceed by a well-worn regulatory pathway with known approvable endpoints, it may not only be the least innovative but also the least commercially successful strategy. Because surrogate markers of efficacy are only theoretically attractive but still largely elusive for psychiatric disorders, drug development strategies may need to proceed instead by opportunistic capturing of signals from clinical use of new agents once they enter clinical practice. Outcomes and dosing for clinical trial populations may not match those in clinical practice, so observations from clinical practice must feedback into new clinical trials. In many ways, once efficacy is proven for the originally targeted indication, drug development begins afresh. To get to secondary stages of novel indications for psychiatric drugs and thus to maximize each drug’s therapeutic potential, evidence-based prescribing is followed by prescribing-based evidence, namely feedback from clinical practice into clinical proof-of-concept studies followed by large-scale studies and new indications. In many cases, the new indications are the more important therapeutic contributions and the most successful commercial application of a drug. Here we describe this strategy of psychiatric drug development and provide numerous examples.
Article PDF
Similar content being viewed by others
References
Stahl SM. Needs and opportunities for innovation in psychopharmacology. J Royal Soc Med 80: 413–417, 1987.
Stahl SM. Does evidence from clinical trials in psychopharmacology apply in clinical practice? J Clin Psychiatry 62: 6–7, 2001.
Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work—from receptors to reality. NeuroRx 3: 10–21, 2006.
Stahl SM. Essential psychopharmacology. 2nd ed. New York: Cambridge University Press, 2000.
Stahl SM. Essential psychopharmacology: the prescriber’s guide. New York: Cambridge University Press, 2005.
Physician’s desk reference, 2005.
Blasi G, Bertolino A. Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx 3: 117–130, 2006.
Apud JA. The pharmocogenomics of the dorsolateral prefrontal cortex: a new tool for the development of “target-oriented” cognitive enhancing drugs. NeuroRx 3: 106–116, 2006.
Simon AB, Gorman JM. Advances in the treatment of anxiety: targeting glutamate. NeuroRx 3: 57–68, 2006.
Carlson PJ, Singh JB, Zarate CA Jr, Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 3: 22–41, 2006.
Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3: 69–81, 2006.
Stahl SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry 64: 355–356, 2002.
Stahl SM. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry 63: 56–57, 2002.
Holzheimer PE III, Nemeroff CB. Advances in the treatment of depression. NeuroRx 3: 42–56, 2006.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stahl, S.M. Finding what you are not looking for: Strategies for developing novel treatments in psychiatry. NeuroRX 3, 3–9 (2006). https://doi.org/10.1016/j.nurx.2005.12.002
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.nurx.2005.12.002